Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2
Longleaf Partners, managed by Southeastern Asset Management, released its second-quarter 2026 investor letter for its “Partners Fund”. A copy of the letter can be downloaded here.







